PRKCD and melanoma: Moreover, when 10μM arachidonyl trifluoromethyl ketone (ATK; a cPLA2 inhibitor) is treated in PKCδ deficient B16F10 melanoma, it failed to augment ceramide generation (Figure 4E) and apoptosis (Figure 4F) in cisplatin treated cells.